Cardinal Health: Competition, Legal Crisis, and Market Position
This paper analyzes the competitive landscape facing Cardinal Health, a Fortune 500 pharmaceutical distributor generating approximately $103 billion in annual revenue. It examines the company's legal and ethical crisis stemming from DEA charges related to the distribution of excessive quantities of oxycodone through its Lakeland, Florida hub. The paper evaluates how these challenges compound Cardinal's competitive vulnerabilities relative to McKesson Corporation and AmerisourceBergen, exploring the structural differences among the three companies — including business model diversification, customer base composition, and revenue segmentation — and assesses Cardinal Health's strategic efforts to insulate itself from industry-wide risks.
- Introduction: Cardinal Health in a Competitive Landscape: Overview of Cardinal Health's revenues and competitive threats
- DEA Charges and the Oxycodone Distribution Crisis: DEA suspension over excessive oxycodone distribution in Florida
- Ethical Failures and Reputational Risk: Ethical lapses and painkiller death spike damage reputation
- Competitive Advantages of McKesson and AmerisourceBergen: Competitors' diversified models insulate them from Cardinal's risks
- Cardinal Health's Diversification Strategy: Cardinal's segmented portfolio as a competitive hedge
- Conclusion: Competitive hierarchy likely to shift as legal dust settles
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its argument in specific financial and legal details — DEA suspension orders, revenue figures, and business segment breakdowns — giving the analysis credibility and precision.
- It effectively connects micro-level corporate misconduct (the Lakeland hub oxycodone case) to macro-level competitive consequences, showing how legal exposure translates into market disadvantage.
- The contrast between Cardinal Health's pure-play middleman model and its competitors' more diversified or insulated structures is used clearly to explain relative vulnerability.
Key academic technique demonstrated
The paper demonstrates comparative competitive analysis by placing Cardinal Health's weaknesses directly alongside the structural strengths of McKesson and AmerisourceBergen. Rather than evaluating Cardinal in isolation, the author uses competitor profiles as a benchmark, a technique aligned with Porter's competitive framework and standard business case analysis.
Structure breakdown
The paper opens by introducing the competitive and regulatory environment before pivoting to Cardinal's DEA indictment as the central crisis. It then layers in ethical considerations, followed by an analysis of how competitors benefit from Cardinal's vulnerabilities. The paper closes by acknowledging Cardinal's diversification efforts while cautioning that competitor advantages may ultimately prove decisive.
Introduction: Cardinal Health in a Competitive Landscape
The pharmaceutical and generic drug industries are highly competitive and, simultaneously, tremendously risk-oriented. Both of these characteristics are significantly present in the current outlook for Cardinal Health. The producer and distributor of generic drugs is a Fortune 500 company which, according to Leger (2012), generates roughly $103 billion in revenue on an annual basis. However, the company is also the target of fierce competition from fellow pharmaceutical giants such as the McKesson Corporation and AmerisourceBergen, and faces troubling legal charges that threaten to impact both its reputation and its profitability. As the discussion here will demonstrate, these competitors have seized a relative competitive advantage over Cardinal Health. The discussion assesses the nature of the challenges thereby imposed upon Cardinal Health.
Create your account
Always verify citation format against your institution’s current style guide requirements.